---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-014834"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:33:50.061348+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology appoints Marianne De Backer as CEO effective April 3, 2023; George Scangos retires

## Summary
- George Scangos notified Board of retirement as CEO and President, effective April 3, 2023.
- Marianne De Backer (ex-Bayer EVP) appointed CEO and Class II director effective same date.
- De Backer receives $900K base salary, 80% target bonus, $5M sign-on bonus in two installments.
- Equity awards valued up to $45M (1,152,904 stock options + 576,452 RSUs) vesting over 4 years.
- Relocation package: $21K/month for up to 18 months plus final moving expenses to San Francisco.

## SEC filing metadata
- accession: 0001193125-23-014834
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523014834/0001193125-23-014834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523014834/d306400d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-014834
- JSON: https://secwatch.observer/filing/0001193125-23-014834.json
- Plain text: https://secwatch.observer/filing/0001193125-23-014834.txt

## Key facts
- Executive change
  Marianne De Backer was appointed as Class II director at Vir Biotechnology, Inc..
  - Action: appointed
  - Role: Class II director
  source text: In addition, effective as of the Effective Date, the size of the Board will increase to 11 directors and Dr. De Backer will be appointed to fill the newly created vacancy to serve on the Board as a Class II director until the Company’s 2024 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523014834/0001193125-23-014834-index.htm
- Executive change
  George Scangos retired as Chief Executive Officer and President at Vir Biotechnology, Inc..
  - Action: retired
  - Role: Chief Executive Officer and President
  source text: On January 19, 2023, George Scangos, Ph.D., notified the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) of his decision to retire as Chief Executive Officer and President effective as of the Effective Date (as defined below).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523014834/0001193125-23-014834-index.htm
- Executive change
  Marianne De Backer was appointed as Chief Executive Officer at Vir Biotechnology, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 19, 2023, the Board appointed Marianne De Backer, MSc, Ph.D., MBA, as Chief Executive Officer of the Company, effective as of April 3, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523014834/0001193125-23-014834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.